{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:58:10Z","timestamp":1785506290115,"version":"3.56.0"},"reference-count":45,"publisher":"Akademiai Kiado Zrt.","issue":"19","license":[{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2026,5,10]]},"abstract":"<jats:p>\n                    A k\u00f6zlem\u00e9ny a tumorinfiltr\u00e1l\u00f3 lymphocyt\u00e1kon (TIL-eken) alapul\u00f3 immunter\u00e1pia\n                    fejl\u0151d\u00e9s\u00e9t tekinti \u00e1t,\n                    <jats:italic>Rosenberg, Spiess \u00e9s Lafreniere<\/jats:italic>\n                    \u00fatt\u00f6r\u0151\n                    munk\u00e1j\u00e1t\u00f3l a lifileucelnek, az els\u0151, szolid tumorokra j\u00f3v\u00e1hagyott sejtter\u00e1pi\u00e1nak\n                    a 2024. \u00e9vi enged\u00e9lyez\u00e9s\u00e9ig. A TIL-ter\u00e1pia el\u0151nye a kim\u00e9ra antig\u00e9nreceptor (CAR)\n                    T-sejt-ter\u00e1pia technol\u00f3gi\u00e1j\u00e1val szemben a poliklon\u00e1lis\n                    T-sejt-receptor-reperto\u00e1r, amely lehet\u0151v\u00e9 teszi a heterog\u00e9n daganatsejtek\n                    hat\u00e9konyabb felismer\u00e9s\u00e9t. A m\u00f3dszer l\u00e9nyege, hogy a beteg saj\u00e1t daganat\u00e1b\u00f3l\n                    izol\u00e1lt lymphocyt\u00e1kat\n                    <jats:italic>ex vivo<\/jats:italic>\n                    felszapor\u00edtj\u00e1k \u00e9s aktiv\u00e1lj\u00e1k,\n                    majd lymphodepleti\u00f3s kezel\u00e9st k\u00f6vet\u0151en visszajuttatj\u00e1k a szervezetbe. Az\n                    \u00f6sszefoglal\u00f3 r\u00e9szletezi a technol\u00f3giai fejl\u0151d\u00e9st, kiemelve a \u201eyoung TIL\u201d\n                    protokollok jelent\u0151s\u00e9g\u00e9t, amelyek a teny\u00e9szt\u00e9si id\u0151 ler\u00f6vid\u00edt\u00e9s\u00e9vel meg\u0151rzik a\n                    sejtek proliferat\u00edv potenci\u00e1lj\u00e1t, \u00e9s megakad\u00e1lyozz\u00e1k a termin\u00e1lis\n                    differenci\u00e1l\u00f3d\u00e1st. Kit\u00e9r a jelenlegi kih\u00edv\u00e1sokra is, mint a tumorreakt\u00edv sejtek\n                    prec\u00edzebb szelekci\u00f3ja, a tumorba val\u00f3 migr\u00e1ci\u00f3 jav\u00edt\u00e1sa \u00e9s a kezel\u00e9shez t\u00e1rsul\u00f3\n                    sziszt\u00e9m\u00e1s toxicit\u00e1s cs\u00f6kkent\u00e9se. Az \u00fajgener\u00e1ci\u00f3s fejleszt\u00e9sek, p\u00e9ld\u00e1ul az\n                    alternat\u00edv citokinek \u00e9s a g\u00e9nm\u00f3dos\u00edtott TIL-k\u00e9sz\u00edtm\u00e9nyek c\u00e9lja a nagy d\u00f3zis\u00fa\n                    IL-2 \u00e9s az intenz\u00edv kemoter\u00e1pia kiv\u00e1lt\u00e1sa, ez\u00e1ltal a mell\u00e9khat\u00e1sok m\u00e9rs\u00e9kl\u00e9se.\n                    \u00d6sszess\u00e9g\u00e9ben a lifileucel j\u00f3v\u00e1hagy\u00e1sa bizony\u00edtja a TIL-ter\u00e1pia\n                    l\u00e9tjogosults\u00e1g\u00e1t, a technol\u00f3gia finomhangol\u00e1s\u00e1val pedig a m\u00f3dszer a j\u00f6v\u0151ben m\u00e1s\n                    szolid daganatok kezel\u00e9s\u00e9re is lehet\u0151s\u00e9get ny\u00fajthat, jelent\u0151sen hozz\u00e1j\u00e1rulva a\n                    r\u00e1kgy\u00f3gy\u00edt\u00e1shoz. Orv Hetil. 2026; 167(19): 740\u2013745.\n                  <\/jats:p>","DOI":"10.1556\/650.2026.33557","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T01:41:22Z","timestamp":1778463682000},"page":"740-745","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["A tumorinfiltr\u00e1l\u00f3 lymphocytak\u00e9sz\u00edtm\u00e9nyek 40 \u00e9ve a r\u00e1k elleni k\u00fczdelemben"],"prefix":"10.1556","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2591-0189","authenticated-orcid":true,"given":"S\u00e1muel","family":"Bal\u00e1zs","sequence":"first","affiliation":[{"name":"HUN\u2013REN Term\u00e9szettudom\u00e1nyi Kutat\u00f3k\u00f6zpont, Molekul\u00e1ris \u00c9lettudom\u00e1nyi Int\u00e9zet Budapest, Magyar Tud\u00f3sok k\u00f6r\u00fatja 2., 1117 Magyarorsz\u00e1g"},{"name":"Semmelweis Egyetem, Doktori Iskola Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318-1321. https:\/\/doi.org\/10.1126\/science.3489291","DOI":"10.1126\/science.3489291"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Chen R, Johnson J, Rezazadeh A, et al. Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges. BMJ Oncol. 2025; 4: e000566. https:\/\/doi.org\/10.1136\/bmjonc-2024-000566","DOI":"10.1136\/bmjonc-2024-000566"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Gooden MJ, De Bock GH, Leffers N, et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011; 105: 93-103. https:\/\/doi.org\/10.1038\/bjc.2011.189","DOI":"10.1038\/bjc.2011.189"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Maibach F, Sadozai H, Seyed Jafari SM, et al. Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma. Front Immunol. 2020; 11: 2105. https:\/\/doi.org\/10.3389\/fimmu.2020.02105","DOI":"10.3389\/fimmu.2020.02105"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348: 203-213. https:\/\/doi.org\/10.1056\/NEJMoa020177","DOI":"10.1056\/NEJMoa020177"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Kumar A, Watkins R, Vilgelm AE. Cell therapy with TILs: training and taming T cells to fight cancer. Front Immunol. 2021; 12: 690499. https:\/\/doi.org\/10.3389\/fimmu.2021.690499","DOI":"10.3389\/fimmu.2021.690499"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Wang S, Sun J, Chen K, et al. Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors. BMC Med. 2021; 19: 140. https:\/\/doi.org\/10.1186\/s12916-021-02006-4","DOI":"10.1186\/s12916-021-02006-4"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"T\u00f3th T, Alizadeh H. On the threshold of a possible cure: innovations in treating multiple myeloma. [Az el\u00e9rhet\u0151 gy\u00f3gyul\u00e1s k\u00fcsz\u00f6b\u00e9n: innov\u00e1ci\u00f3k a myeloma multiplex kezel\u00e9s\u00e9ben.] Orv Hetil. 2024; 165: 891-899. https:\/\/doi.org\/10.1556\/650.2024.33036","DOI":"10.1556\/650.2024.33036"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Yang J, Ding X, Fang Z, et al. Association of CD8+ tumor-infiltrating lymphocytes co-expressing granzyme A and interferon-\u03b3 with colon cancer cells in the tumor microenvironment. BMC Cancer 2024; 24: 869. https:\/\/doi.org\/10.1186\/s12885-024-12605-y","DOI":"10.1186\/s12885-024-12605-y"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Qiu X, Li S, Fan T, et al. Advances and prospects in tumor infiltrating lymphocyte therapy. Discov Oncol. 2024; 15: 630. https:\/\/doi.org\/10.1007\/s12672-024-01410-5","DOI":"10.1007\/s12672-024-01410-5"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Klobuch S, Seijkens TT, Schumacher TN, et al. Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma. Nat Rev Clin Oncol. 2024; 21: 173-184. https:\/\/doi.org\/10.1038\/s41571-023-00848-w","DOI":"10.1038\/s41571-023-00848-w"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Shaik R, Shaik R, Royyala SA, et al. Tumor infiltration therapy: from FDA approval to next-generation approaches. Clin Exp Med. 2025; 25: 254. https:\/\/doi.org\/10.1007\/s10238-025-01574-6","DOI":"10.1007\/s10238-025-01574-6"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994; 86: 1159-1166. https:\/\/doi.org\/10.1093\/jnci\/86.15.1159","DOI":"10.1093\/jnci\/86.15.1159"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Scheper W, Kelderman S, Fanchi LF, et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat Med. 2019; 25: 89-94. https:\/\/doi.org\/10.1038\/s41591-018-0266-5","DOI":"10.1038\/s41591-018-0266-5"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Dudley ME, Wunderlich J, Nishimura MI, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother. 2001; 24: 363-373. https:\/\/doi.org\/10.1097\/00002371-200107000-00012","DOI":"10.1097\/00002371-200107000-00012"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Fry TJ, Mackall CL. Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol. 2001; 22: 564-571. https:\/\/doi.org\/10.1016\/S1471-4906(01)02028-2","DOI":"10.1016\/S1471-4906(01)02028-2"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Dudley ME, Wunderlich JR, Yang JC, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 2002; 25: 243-251. https:\/\/doi.org\/10.1097\/00002371-200205000-00007","DOI":"10.1097\/00002371-200205000-00007"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-854. https:\/\/doi.org\/10.1126\/science.1076514","DOI":"10.1126\/science.1076514"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Dudley ME, Gross CA, Langhan MM, et al. CD8+ enriched \u2018young\u2019 tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res. 2010; 16: 6122-6131. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1297","DOI":"10.1158\/1078-0432.CCR-10-1297"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015; 15: 486-499. https:\/\/doi.org\/10.1038\/nri3862","DOI":"10.1038\/nri3862"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Tran KQ, Zhou J, Durflinger KH, et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother. 2008; 31: 742-751. https:\/\/doi.org\/10.1097\/CJI.0b013e31818403d5","DOI":"10.1097\/CJI.0b013e31818403d5"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Dafni U, Michielin O, Lluesma SM, et al. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Ann Oncol. 2019; 30: 1902-1913. https:\/\/doi.org\/10.1093\/annonc\/mdz398","DOI":"10.1093\/annonc\/mdz398"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Lowery FJ, Krishna S, Yossef R, et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 2022; 375: 877-884. https:\/\/doi.org\/10.1126\/science.abl5447","DOI":"10.1126\/science.abl5447"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Fernandez-Poma SM, Salas-Benito D, Lozano T, et al. Expansion of tumor-infiltrating CD8+ T cells expressing PD-1 improves the efficacy of adoptive T-cell therapy. Cancer Res. 2017; 77: 3672-3684. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0236","DOI":"10.1158\/0008-5472.CAN-17-0236"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Krishna S, Lowery FJ, Copeland AR, et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science 2020; 370: 1328-1334. https:\/\/doi.org\/10.1126\/science.abb9847","DOI":"10.1126\/science.abb9847"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Bidar F, Hamada S, Gossez M, et al. Recombinant human interleukin-7 reverses T cell exhaustion ex vivo in critically ill COVID-19 patients. Ann Intensive Care 2022; 12: 21. Erratum: Ann Intensive Care 2022; 12: 30. https:\/\/doi.org\/10.1186\/s13613-022-01007-7","DOI":"10.1186\/s13613-022-01007-7"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Saito M, Inoue S, Yamashita K, et al. IL-15 improves aging-induced persistent T cell exhaustion in mouse models of repeated sepsis. Shock 2020; 53: 228-235. https:\/\/doi.org\/10.1097\/SHK.0000000000001352","DOI":"10.1097\/SHK.0000000000001352"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Ao YQ, Gao J, Zhang LX, et al. Tumor-infiltrating CD36+CD8+T cells determine exhausted tumor microenvironment and correlate with inferior response to chemotherapy in non-small cell lung cancer. BMC Cancer 2023; 23: 367. https:\/\/doi.org\/10.1186\/s12885-023-10836-z","DOI":"10.1186\/s12885-023-10836-z"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Jin J, Sabatino M, Somerville R, et al. Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment. J Immunother. 2012; 35: 283-292. https:\/\/doi.org\/10.1097\/CJI.0b013e31824e801f","DOI":"10.1097\/CJI.0b013e31824e801f"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Crossey F, Marx S, H\u00f6lters S, et al. Robust method for isolation of tumor infiltrating lymphocytes with a high vital cell yield from small samples of renal cell carcinomas by a new collagenase-free mechanical procedure. Urol Oncol. 2018; 36: 402.e1-402.e10. https:\/\/doi.org\/10.1016\/j.urolonc.2018.06.002","DOI":"10.1016\/j.urolonc.2018.06.002"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Castle JC, Kreiter S, Diekmann J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 2012; 72: 1081-1091. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3722","DOI":"10.1158\/0008-5472.CAN-11-3722"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Kalaora S, Barnea E, Merhavi-Shoham E, et al. Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. Oncotarget 2016; 7: 5110-5117. https:\/\/doi.org\/10.18632\/oncotarget.6960","DOI":"10.18632\/oncotarget.6960"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Vignali D, Kallikourdis M. Improving homing in T cell therapy. Cytokine Growth Factor Rev. 2017; 36: 107-116. https:\/\/doi.org\/10.1016\/j.cytogfr.2017.06.009","DOI":"10.1016\/j.cytogfr.2017.06.009"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Foeng J, Comerford I, McColl SR. Harnessing the chemokine system to home CAR-T cells into solid tumors. Cell Rep Med. 2022; 3: 100543. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100543","DOI":"10.1016\/j.xcrm.2022.100543"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Mao X, Xu J, Wang W, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer 2021; 20: 131. https:\/\/doi.org\/10.1186\/s12943-021-01428-1","DOI":"10.1186\/s12943-021-01428-1"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Martin JD, Seano G, Jain RK. Normalizing function of tumor vessels: progress, opportunities, and challenges. Annu Rev Physiol. 2019; 81: 505-534. https:\/\/doi.org\/10.1146\/annurev-physiol-020518-114700","DOI":"10.1146\/annurev-physiol-020518-114700"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Kurtulus S, Madi A, Escobar G, et al. Checkpoint blockade immunotherapy induces dynamic changes in PD-1\u2212CD8+ tumor-infiltrating T cells. Immunity 2019; 50: 181-194.e6. https:\/\/doi.org\/10.1016\/j.immuni.2018.11.014","DOI":"10.1016\/j.immuni.2018.11.014"},{"key":"R38","doi-asserted-by":"crossref","unstructured":"Barsi H, Fazekas B, Nagy ZZs, et al. Review of paraneoplastic retinopathies illustrated by two case reports. [Az idegh\u00e1rty\u00e1t \u00e9rint\u0151 paraneoplasi\u00e1s szindr\u00f3m\u00e1k \u00e1ttekint\u00e9se k\u00e9t eset illusztr\u00e1l\u00e1s\u00e1val.] Orv Hetil. 2025; 166: 1898-1907. [Hungarian] https:\/\/doi.org\/10.1556\/650.2025.33434","DOI":"10.1556\/650.2025.33434"},{"key":"R39","doi-asserted-by":"crossref","unstructured":"Khoja LT, Nguyen L, Wang L, et al. A phase II study Evaluating the infusion of autologous tumor-infiltrating lymphocytes and low-dose interleukin-2 therapy following non-myeloablative lymphodepletion using cyclophosphamide and fludarabine in patients with metastatic melanoma. Ann Oncol. 2014; 25: iv391. https:\/\/doi.org\/10.1093\/annonc\/mdu344.44","DOI":"10.1093\/annonc\/mdu344.44"},{"key":"R40","doi-asserted-by":"crossref","unstructured":"Nissani A, Lev-Ari S, Meirson T, et al. Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy. J Immunother Cancer 2021; 9: e001743. https:\/\/doi.org\/10.1136\/jitc-2020-001743","DOI":"10.1136\/jitc-2020-001743"},{"key":"R41","doi-asserted-by":"crossref","unstructured":"Guo J, Luo N, Ai G, et al. Eradicating tumor in a recurrent cervical cancer patient with autologous tumor-infiltrating lymphocytes and a modified lymphodepleting regimen. J Immunother Cancer 2022; 10: e003887. https:\/\/doi.org\/10.1136\/jitc-2021-003887","DOI":"10.1136\/jitc-2021-003887"},{"key":"R42","doi-asserted-by":"crossref","unstructured":"Joerger M, Calvo E, Laubli H, et al. Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed or refractory advanced solid tumors. J Immunother Cancer 2023; 11: e007784. https:\/\/doi.org\/10.1136\/jitc-2023-007784","DOI":"10.1136\/jitc-2023-007784"},{"key":"R43","doi-asserted-by":"crossref","unstructured":"Amaria RN, McQuade JL, Davies MA, et al. OBX-115, an interleukin 2-sparing engineered tumor-infiltrating lymphocyte cell therapy in patients with immune checkpoint inhibitor-resistant unresectable or metastatic melanoma. J Clin Oncol. 2024; 42: 9515. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.9515","DOI":"10.1200\/JCO.2024.42.16_suppl.9515"},{"key":"R44","doi-asserted-by":"crossref","unstructured":"Keam SJ. Lifileucel: first approval. Mol Diagn Ther. 2024; 28: 339-344. https:\/\/doi.org\/10.1007\/s40291-024-00708-y","DOI":"10.1007\/s40291-024-00708-y"},{"key":"R45","doi-asserted-by":"crossref","unstructured":"Kwong ML, Yang JC. Lifileucel: FDA-approved T-cell therapy for melanoma. Oncologist 2024; 29: 648-650. https:\/\/doi.org\/10.1093\/oncolo\/oyae136","DOI":"10.1093\/oncolo\/oyae136"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/19\/article-p740.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/19\/article-p740.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/19\/article-p740.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T12:59:44Z","timestamp":1785502784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/19\/article-p740.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,10]]},"references-count":45,"journal-issue":{"issue":"19"},"URL":"https:\/\/doi.org\/10.1556\/650.2026.33557","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,10]]}}}